source
- FDA urges biosimilar sponsors to use alternative efficacy studies while AI reshapes regulatory workAI is becoming common in regulatory work. Experts say it will not replace regulatory professionals but will help them work more efficiently and free up time for human interaction. They stress that…
- FDA urges biosimilar makers to adopt alternatives to clinical efficacy trialsFDA's Office of Therapeutic Biologics and Biosimilars, led by director Sarah Yim, announced that the agency is working to help sponsors rely less on clinical efficacy studies when developing biosim…